ME Therapeutics Holdings Inc. (CSE:METX)

Canada flag Canada · Delayed Price · Currency is CAD
10.50
0.00 (0.00%)
Mar 28, 2025, 4:00 PM EST
199.15%
Market Cap 274.99M
Revenue (ttm) n/a
Net Income (ttm) -1.25M
Shares Out 26.19M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 257
Open 10.50
Previous Close 10.50
Day's Range 10.50 - 10.50
52-Week Range 0.75 - 11.00
Beta n/a
RSI 69.10
Earnings Date Mar 21, 2025

About ME Therapeutics Holdings

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno‐oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol METX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.